Johnson & Johnson talc-based baby powder sales will soon cease in North America; CMS provides detailed guidance on how to reopen nursing homes to visitors; CDC provides additional information for schools and business looking to resume operations.
Pharmaceutical giant Johnson & Johnson (J&J) will soon halt sales of its controversial talc-based baby powder in the United States and Canada, reports The New York Times. All product currently remaining on store shelves can be sold, but once gone, these supplies will not be replenished. Sales of powder formulations with cornstarch will continue, while the talc-based powder will still be available in other countries. J&J has faced criticism over the years, defending its signature powder from countless lawsuits and claims that it contains asbestos and causes cancer.
Nine pages of guidance from CMS detail how nursing homes can safely reopen to visitors in 3 phases. Phase 1 involves testing all residents and staff, as well as screening staff daily, in addition to facility inspections as necessary. Phase 2 will commence when, among other factors, there have been no new cases for 2 weeks and there are enough personal protective equipment and cleaning supplies; some visitation can also start in the phase. Phase 3 starts when all phase 2 criteria have been met, including no rebound cases. Nursing homes have been especially hard hit by the coronavirus disease 2019 (COVID-19) pandemic, with close to one-third of deaths from the virus being residents or staff at these facilities.
All 50 states have reopened or are starting to, and a revision to a CDC report previously shelved has now been released to help schools, business, and transit systems, as well as numerous other industries, come back online, according to The New York Times. Flexibilty lies at the heart of the 60-page document and centers on providing ongoing testing, depending on risk of exposure to COVID-19; instituting strict rules on hygiene; and coordinating with local health officials on maximum prevention efforts. The report comes on the heels of checklists that the CDC released last week specifically to help school and business make the most informed decisions on when to reopen.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More